Cardiac Computed Tomography In the Management of Patients With indeterminAte or inConclusive Stress Tests (CT-MPACT)

March 20, 2012 updated by: Kavitha Chinnaiyan, William Beaumont Hospitals

Coronary CT angiography (CCTA) offers great promise as a risk stratification tool in patients with suspected CAD. It has been demonstrated in a multitude of accuracy studies to have a negative predictive value averaging over 95%. This leads to the hypothesis that a negative CCTA may preclude the need for invasive testing. The purpose of this randomized controlled study is to prospectively evaluate the role of CCTA on the management of patients with inconclusive or indeterminate stress test results.CCTA is able to provide not only information on presence and extent of coronary artery calcification, but detailed coronary anatomy as well.

SPECIFIC AIM # 1: To evaluate the diagnostic and prognostic performance of CCTA in patients with equivocal / intermediate stress test results as compared to conventional invasive coronary angiography.

SPECIFIC AIM # 2: To evaluate the utility of CCTA in prediction of major adverse cardiac events (MACE) compared to invasive coronary angiography at 30 days, 1 year, 3 years and 5 years.

Study Overview

Status

Completed

Conditions

Detailed Description

Outpatients scheduled to undergo cardiac catheterization and coronary angiography for the specific indication of inconclusive or indeterminate stress tests will be considered for this study. Patients will be initially screened by their cardiologist for the presence of inclusion/exclusion criteria, as well as pre-test and post-test likelihood of CAD.16, 17 All patients must have undergone a stress (exercise or pharmacologic) test within the past 3 months.

After consent, patients will be randomized 1:1 to undergo CCTA or cardiac catheterization. The decision whether or not to proceed with subsequent invasive cardiac catheterization (CCTA arm) or revascularization (catheterization arm) will be made by the patient's primary and interventional cardiologists respectively.

Inclusion:

  1. Chest pain or other symptoms suggestive of coronary artery disease.
  2. Pharmacologic/exercise stress test with SPECT (nuclear myocardial-heart perfusion imaging) within the past 3 months.
  3. "Discordant or conflicting findings" clinical and stress results as outlined above.
  4. Scheduled to undergo cardiac catheterization.
  5. Able to provide informed consent.
  6. Age equal to or greater than 18 years.

Exclusion:

  1. Presence of pre-existing heart disease (prior heart attack, prior angiographic evidence of significant heart disease, prior heart surgery) or cardiomyopathy (ejection fraction less than or equal to 45%)
  2. History of high blood pressure with severe left ventricular hypertrophy (thicken heart muscle), history of cor pulmonale (right heart chamber failure due to elevated blood pressures in the arteries delivering blood to the lungs).
  3. Kidney insufficiency (creatinine greater than or equal to 1.6) or kidney failure requiring dialysis.
  4. Inability or refusal to provide informed consent.
  5. Psychological unsuitability or extreme claustrophobia (fear of closed in spaces).
  6. Pregnancy or unknown pregnancy status.
  7. Age less than 18 years.
  8. Patients with known allergy to iodinated contrast, unable to tolerate pre-medication.
  9. Inability to tolerate beta-blockers (medication to slow the heart rate), including those with COPD or asthma requiring maintenance inhaled bronchodilators or steroids, complete heart block, second-degree atrioventricular block.
  10. Computed tomography imaging, or contrast administration, within the past 48 hours.

Study Type

Observational

Enrollment (Actual)

45

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Michigan
      • Royal Oak, Michigan, United States, 48073
        • William Beaumont Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Volunteers over 18 years of age; both genders; referred from participating cardiologist's offices

Description

Inclusion Criteria:

  1. Chest pain or other symptoms suggestive of coronary artery disease.
  2. Pharmacologic/exercise stress test with SPECT within the past 3 months.
  3. "Discordant" clinical and stress results as outlined above.
  4. Scheduled to undergo cardiac catheterization.
  5. Able to provide informed consent.
  6. Age equal to or greater than 18 years.

Exclusion Criteria:

  1. Presence of pre-existing CAD (prior myocardial infarction, prior angiographic evidence of significant coronary artery disease, prior coronary bypass surgery) or cardiomyopathy (ejection fraction < 45%)
  2. History of hypertension with severe left ventricular hypertrophy, history of cor pulmonale.
  3. Renal insufficiency (creatinine ≥1.6) or renal failure requiring dialysis.
  4. Inability or refusal to provide informed consent.
  5. Psychological unsuitability or extreme claustrophobia.
  6. Pregnancy or unknown pregnancy status.
  7. Age less than 18 years.
  8. Patients with known allergy to iodinated contrast, unable to tolerate pre-medication.
  9. Inability to tolerate beta-blockers, including those with COPD or asthma requiring maintenance inhaled bronchodilators or steroids, complete heart block, second-degree atrioventricular block.
  10. Computed tomography imaging, or contrast administration, within the past 48 hours.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Kavitha Chinnaiyan, MD, William Beaumont Hospitals
  • Study Director: Gilbert Raff, MD, William Beaumont Hospitals

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2007

Primary Completion (Actual)

June 1, 2011

Study Completion (Actual)

June 1, 2011

Study Registration Dates

First Submitted

October 9, 2007

First Submitted That Met QC Criteria

October 9, 2007

First Posted (Estimate)

October 10, 2007

Study Record Updates

Last Update Posted (Estimate)

March 21, 2012

Last Update Submitted That Met QC Criteria

March 20, 2012

Last Verified

March 1, 2012

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronary Disease

3
Subscribe